Other Clinical Trial - A Study of SPH3127 in the Treatment of Mild to

See also
Status	Clinical Trial	Phase
Completed	`NCT01201122` - Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis	Phase 4
Completed	`NCT01033305` - Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)	Phase 2
Completed	`NCT01045018` - A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis	Phase 3
Recruiting	`NCT01039597` - Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis	Phase 1/Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT01201122 - Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis

Phase 4

Completed

NCT01033305 - Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)

Phase 2

Completed

NCT01045018 - A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis

Phase 3

Recruiting

NCT01039597 - Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

Phase 1/Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05770609
Study type	Interventional
Source	Shanghai Pharmaceuticals Holding Co., Ltd
Contact	Minhu Chen
Phone	0086-020-87755766
Email	chenminhu@vip.163.com
Status	Recruiting
Phase	Phase 2
Start date	June 19, 2023
Completion date	February 15, 2025

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms